{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T03:08:31Z","timestamp":1785294511490,"version":"3.55.0"},"reference-count":89,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T00:00:00Z","timestamp":1742169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T00:00:00Z","timestamp":1742169600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["AG000994"],"award-info":[{"award-number":["AG000994"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020206","name":"Korea Dementia Research Center","doi-asserted-by":"publisher","award":["RS-2024-0034124913"],"award-info":[{"award-number":["RS-2024-0034124913"]}],"id":[{"id":"10.13039\/100020206","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004080","name":"Korea Drug Development Fund","doi-asserted-by":"publisher","award":["KDDF RS-2024-00338017"],"award-info":[{"award-number":["KDDF RS-2024-00338017"]}],"id":[{"id":"10.13039\/501100004080","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100020363","name":"Institute for Information Industry, Ministry of Science and Technology, Taiwan","doi-asserted-by":"publisher","award":["MOST 111-2314-B-038 -134 -MY3"],"award-info":[{"award-number":["MOST 111-2314-B-038 -134 -MY3"]}],"id":[{"id":"10.13039\/501100020363","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Taipei Medical University-Case Western University Cooperative Research Agreement","award":["TMU 112-3805-001-400"],"award-info":[{"award-number":["TMU 112-3805-001-400"]}]},{"DOI":"10.13039\/100008564","name":"School of Medicine, Case Western Reserve University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["GeroScience"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>An overactive neuroinflammatory response is often evident in the elderly and is a significant contributor to brain tissue damage following acute ischemic stroke. Such an inflammatory response is largely mediated by microglial cells and peripheral blood mononuclear cells (PBMCs). Classical anti-inflammatory agents have not proved clinically effective in mitigating the impact of ischemic stroke but have highlighted targets for new drug development, in particular excessive proinflammatory cytokine release. The immunomodulatory imide drug (IMiD) class has shown potential in reducing neuroinflammation and switching microglial phenotypic expression away from a proinflammatory to a regenerative anti-inflammatory one. 3-Monothiopomalidomide (3-MP), a new IMiD, has a brain\/plasma concentration ratio of 0.5 to 0.6, an oral bioavailability of 38.5%, and a monophasic disappearance of half-life 3.2\u00a0h following oral administration. 3-MP pretreatment mitigates lipopolysaccharide (LPS)-induced inflammation in cellular human PBMCs and, in rat studies, 3-MP pretreatment lowers proinflammatory cytokine levels in the conditioned media and in plasma and the brain, respectively. Administered systemically to rats challenged with middle cerebral artery occlusion (MCAo) and reperfusion, 3-MP post-MCAo treatment reduced infarction volume; improved body asymmetry, a behavioral measure of stroke impact; and lowered inflammation. In summary, 3-MP exerted neuroprotective effects via anti-inflammatory actions against MCAo-induced ischemic injury and represents a therapeutic that warrants further investigation as a treatment for brain damage and related disorders associated with excessive inflammation.<\/jats:p>","DOI":"10.1007\/s11357-025-01573-1","type":"journal-article","created":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T04:42:12Z","timestamp":1742186532000},"page":"5763-5783","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["3-Monothiopomalidomide, a new immunomodulatory imide drug (IMiD), blunts inflammation and mitigates ischemic stroke in the rat"],"prefix":"10.1007","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2941-3197","authenticated-orcid":false,"given":"Kai-Yun","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-0838-0223","authenticated-orcid":false,"given":"Shih-Chang","family":"Hsueh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4385-751X","authenticated-orcid":false,"given":"Pathik","family":"Parekh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1505-9334","authenticated-orcid":false,"given":"Buyandelger","family":"Batsaikhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8446-4544","authenticated-orcid":false,"given":"David","family":"Tweedie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiming","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chirag","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8426-4016","authenticated-orcid":false,"given":"Yung-Hsiao","family":"Chiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6780-9432","authenticated-orcid":false,"given":"Nicholas","family":"Bambakidis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barry J.","family":"Hoffer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi-Zong","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seong-Jin","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuo-Jen","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eunji","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong Seok","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3032-1468","authenticated-orcid":false,"given":"Nigel H.","family":"Greig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,17]]},"reference":[{"issue":"22","key":"1573_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/01.NT.0000521171.91100.84","volume":"17","author":"TR Collins","year":"2017","unstructured":"Collins TR. Neurologic diseases found to be the largest cause of disability worldwide. Neurology Today. 2017;17(22):1\u201332.","journal-title":"Neurology Today"},{"issue":"3","key":"1573_CR2","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/j.neuropharm.2008.01.005","volume":"55","author":"KP Doyle","year":"2008","unstructured":"Doyle KP, Simon RP, Stenzel-Poore MP. Mechanisms of ischemic brain damage. Neuropharmacology. 2008;55(3):310\u20138.","journal-title":"Neuropharmacology"},{"issue":"8","key":"1573_CR3","doi-asserted-by":"publisher","first-page":"2697","DOI":"10.1161\/STROKEAHA.121.034388","volume":"52","author":"PJ Kelly","year":"2021","unstructured":"Kelly PJ, Lemmens R, Tsivgoulis G. Inflammation and stroke risk: a new target for prevention. Stroke. 2021;52(8):2697\u2013706.","journal-title":"Stroke"},{"issue":"1","key":"1573_CR4","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1161\/CIRCRESAHA.116.308022","volume":"119","author":"D Petrovic-Djergovic","year":"2016","unstructured":"Petrovic-Djergovic D, Goonewardena SN, Pinsky DJ. Inflammatory disequilibrium in stroke. Circ Res. 2016;119(1):142\u201358.","journal-title":"Circ Res"},{"issue":"9","key":"1573_CR5","doi-asserted-by":"publisher","first-page":"2542","DOI":"10.18632\/aging.101931","volume":"11","author":"M Yousufuddin","year":"2019","unstructured":"Yousufuddin M, Young N. Aging and ischemic stroke. Aging (Albany NY). 2019;11(9):2542\u20134. https:\/\/doi.org\/10.18632\/aging.101931.","journal-title":"Aging (Albany NY)"},{"key":"1573_CR6","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/B978-0-444-64034-5.00014-6","volume":"176","author":"V Singh","year":"2021","unstructured":"Singh V, Cheng R. Neurovascular physiology and neurocritical care. Handb Clin Neurol. 2021;176:71\u201380. https:\/\/doi.org\/10.1016\/B978-0-444-64034-5.00014-6.","journal-title":"Handb Clin Neurol"},{"issue":"23","key":"1573_CR7","doi-asserted-by":"publisher","first-page":"13101","DOI":"10.3390\/ijms222313101","volume":"22","author":"SM Stuckey","year":"2021","unstructured":"Stuckey SM, Ong LK, Collins-Praino LE, Turner RJ. Neuroinflammation as a key driver of secondary neurodegeneration following stroke? Int J Mol Sci. 2021;22(23):13101. https:\/\/doi.org\/10.3390\/ijms222313101.","journal-title":"Int J Mol Sci"},{"issue":"2","key":"1573_CR8","doi-asserted-by":"publisher","first-page":"C135","DOI":"10.1152\/ajpcell.00136.2018","volume":"316","author":"C Yang","year":"2019","unstructured":"Yang C, Hawkins KE, Dor\u00e9 S, Candelario-Jalil E. Neuroinflammatory mechanisms of blood-brain barrier damage in ischemic stroke. Am J Physiol Cell Physiol. 2019;316(2):C135\u201353. https:\/\/doi.org\/10.1152\/ajpcell.00136.2018.","journal-title":"Am J Physiol Cell Physiol"},{"issue":"1","key":"1573_CR9","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1186\/s12974-019-1516-2","volume":"16","author":"RL Jayaraj","year":"2019","unstructured":"Jayaraj RL, Azimullah S, Beiram R, Jalal FY, Rosenberg GA. Neuroinflammation: friend and foe for ischemic stroke. J Neuroinflammation. 2019;16(1):142. https:\/\/doi.org\/10.1186\/s12974-019-1516-2.","journal-title":"J Neuroinflammation"},{"key":"1573_CR10","doi-asserted-by":"publisher","first-page":"294","DOI":"10.3389\/fimmu.2020.00294","volume":"11","author":"S Xu","year":"2020","unstructured":"Xu S, Lu J, Shao A, Zhang JH, Zhang J. Glial cells: role of the immune response in ischemic strokE. Front Immunol. 2020;11:294. https:\/\/doi.org\/10.3389\/fimmu.2020.00294.","journal-title":"Front Immunol"},{"issue":"18","key":"1573_CR11","doi-asserted-by":"publisher","first-page":"6454","DOI":"10.3390\/ijms21186454","volume":"21","author":"CD Maida","year":"2020","unstructured":"Maida CD, Norrito RL, Daidone M, Tuttolomondo A, Pinto A. Neuroinflammatory mechanisms in ischemic stroke: focus on cardioembolic stroke, background, and therapeutic approaches. Int J Mol Sci. 2020;21(18):6454. https:\/\/doi.org\/10.3390\/ijms21186454.","journal-title":"Int J Mol Sci"},{"issue":"2","key":"1573_CR12","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/0022-510x(94)90289-5","volume":"122","author":"K Fassbender","year":"1994","unstructured":"Fassbender K, Rossol S, Kammer T, Daffertshofer M, Wirth S, Dollman M, Hennerici M. Proinflammatory cytokines in serum of patients with acute cerebral ischemia: kinetics of secretion and relation to the extent of brain damage and outcome of disease. J Neurol Sci. 1994;122(2):35\u20139. https:\/\/doi.org\/10.1016\/0022-510x(94)90289-5.","journal-title":"J Neurol Sci"},{"key":"1573_CR13","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.cytogfr.2024.06.002","volume":"78","author":"S Kumari","year":"2024","unstructured":"Kumari S, Dhapola R, Sharma P, Nagar P, Medhi B, HariKrishnaReddy D. The impact of cytokines in neuroinflammation-mediated stroke. Cytokine Growth Factor Rev. 2024;78:105\u201319. https:\/\/doi.org\/10.1016\/j.cytogfr.2024.06.002.","journal-title":"Cytokine Growth Factor Rev"},{"key":"1573_CR14","doi-asserted-by":"publisher","first-page":"175628641878985","DOI":"10.1177\/1756286418789854","volume":"11","author":"A Drieu","year":"2018","unstructured":"Drieu A, Levard D, Vivien D, Rubio M. Anti-inflammatory treatments for stroke: from bench to bedside. Ther Adv Neurol Disord. 2018;11:1756286418789854. https:\/\/doi.org\/10.1177\/1756286418789854.","journal-title":"Ther Adv Neurol Disord"},{"key":"1573_CR15","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1161\/01.STR.0000057976.53301.69","volume":"34","author":"N Vila","year":"2003","unstructured":"Vila N, Castillo J, D\u00e1valos A, Esteve A, Planas AM, Chamorro A. Levels of anti-inflammatory cytokines and neurological worsening in acute ischemic stroke. Stroke. 2003;34:671\u20135. https:\/\/doi.org\/10.1161\/01.STR.0000057976.53301.69.","journal-title":"Stroke"},{"issue":"5","key":"1573_CR16","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1111\/jth.12855","volume":"13","author":"P Garc\u00eda-Poza","year":"2015","unstructured":"Garc\u00eda-Poza P, de Abajo FJ, Gil MJ, Chac\u00f3n A, Bryant V, Garc\u00eda-Rodr\u00edguez LA. Risk of ischemic stroke associated with non-steroidal anti-inflammatory drugs and paracetamol: a population-based case-control study. J Thromb Haemost. 2015;13(5):708\u201318. https:\/\/doi.org\/10.1111\/jth.12855.","journal-title":"J Thromb Haemost"},{"key":"1573_CR17","unstructured":"U.S. Food and Drug Administration. FDA Drug Safety Communication: FDA strengthens warning that non-aspirin nonsteroidal anti-inflammatory drugs (NSAIDs) can cause heart attacks or strokes. https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-drug-safety-communication-fda-strengthens-warning-non-aspirin-nonsteroidal-anti-inflammatory. 7.9.2015 (accessed 11.25.2024)"},{"issue":"9","key":"1573_CR18","doi-asserted-by":"publisher","first-page":"846","DOI":"10.2174\/1568009617666170214104426","volume":"17","author":"S Raza","year":"2017","unstructured":"Raza S, Safyan RA, Lentzsch S. Immunomodulatory drugs (IMiDs) in multiple myeloma. Curr Cancer Drug Targets. 2017;17(9):846\u201357. https:\/\/doi.org\/10.2174\/1568009617666170214104426.","journal-title":"Curr Cancer Drug Targets"},{"key":"1573_CR19","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.ddtec.2019.02.004","volume":"31","author":"PP Chamberlain","year":"2019","unstructured":"Chamberlain PP, Cathers BE. Cereblon modulators: low molecular weight inducers of protein degradation. Drug Discov Today Technol. 2019;31:9\u201334. https:\/\/doi.org\/10.1016\/j.ddtec.2019.02.004.","journal-title":"Drug Discov Today Technol"},{"key":"1573_CR20","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1002\/cpt196563303","volume":"6","author":"J Sheskin","year":"1965","unstructured":"Sheskin J. Thalidomide in the treatment of lepra reactions. Clin Pharmacol Ther. 1965;6:303\u20136. https:\/\/doi.org\/10.1002\/cpt196563303.","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"1573_CR21","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1080\/14740338.2021.1953467","volume":"21","author":"SM de Jesus","year":"2022","unstructured":"de Jesus SM, Santana RS, Leite SN. Comparative analysis of the use and control of thalidomide in Brazil and different countries: is it possible to say there is safety? Expert Opin Drug Saf. 2022;21(1):67\u201381. https:\/\/doi.org\/10.1080\/14740338.2021.1953467.","journal-title":"Expert Opin Drug Saf"},{"issue":"Pt B","key":"1573_CR22","doi-asserted-by":"publisher","first-page":"113240","DOI":"10.1016\/j.intimp.2024.113240","volume":"142","author":"Y Jiang","year":"2024","unstructured":"Jiang Y, Zou Y, Wang H. Review of research progress on different modalities of Macrophage death in Mycobacterium leprae infection. Int Immunopharmacol. 2024;142(Pt B):113240. https:\/\/doi.org\/10.1016\/j.intimp.2024.113240.","journal-title":"Int Immunopharmacol"},{"key":"1573_CR23","doi-asserted-by":"publisher","first-page":"3252","DOI":"10.3390\/ijms19103252","volume":"19","author":"YR Tsai","year":"2018","unstructured":"Tsai YR, Chang CF, Lai JH, Wu JC, Chen YH, Kang SJ, Hoffer BJ, Tweedie D, Luo W, Greig NH, Chiang YH, Chen KY. Pomalidomide ameliorates H(2)O(2)-induced oxidative stress injury and cell death in rat primary cortical neuronal cultures by inducing anti-oxidative and anti-apoptosis effects. Int J Mol Sci. 2018;19:3252. https:\/\/doi.org\/10.3390\/ijms19103252.","journal-title":"Int J Mol Sci"},{"issue":"4","key":"1573_CR24","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1177\/0963689719850078","volume":"28","author":"YR Tsai","year":"2019","unstructured":"Tsai YR, Tweedie D, Navas-Enamorado I, Scerba MT, Chang CF, Lai JH, Wu JC, Chen YH, Kang SJ, Hoffer BJ, de Cabo R, Greig NH, Chiang YH, Chen KY. Pomalidomide reduces ischemic brain injury in rodents. Cell Transplant. 2019;28(4):439\u201350. https:\/\/doi.org\/10.1177\/0963689719850078.","journal-title":"Cell Transplant"},{"key":"1573_CR25","doi-asserted-by":"publisher","first-page":"313","DOI":"10.3389\/fcell.2019.00313","volume":"7","author":"YJ Jung","year":"2019","unstructured":"Jung YJ, Tweedie D, Scerba MT, Greigm NH. Neuroinflammation as a factor of neurodegenerative disease: thalidomide analogs as treatments. Front Cell Dev Biol. 2019;7:313. https:\/\/doi.org\/10.3389\/fcell.2019.00313.","journal-title":"Front Cell Dev Biol"},{"key":"1573_CR26","doi-asserted-by":"publisher","first-page":"e54726","DOI":"10.7554\/eLife.54726","volume":"9","author":"CT Lin","year":"2020","unstructured":"Lin CT, Lecca D, Yang LY, Luo W, Scerba MT, Tweedie D, Huang PS, Jung YJ, Kim DS, Yang CH, Hoffer BJ, Wang JY, Greig NH. 3,6\u2019-dithiopomalidomide reduces neural loss, inflammation, behavioral deficits in brain injury and microglial activation. Elife. 2020;9:e54726. https:\/\/doi.org\/10.7554\/eLife.54726.","journal-title":"Elife"},{"key":"1573_CR27","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1021\/acsptsci.1c00042","volume":"4","author":"SC Hsueh","year":"2021","unstructured":"Hsueh SC, Luo W, Tweedie D, Kim DS, Kim YK, Hwang I, Gil JE, Han BS, Chiang YH, Selman W, Hoffer BJ, Greig NH. N-adamantyl phthalimidine: a new thalidomide-like drug that lacks cereblon binding and mitigates neuronal and synaptic loss, neuroinflammation, and behavioral deficits in traumatic brain injury and LPS challenge. ACS Pharmacol Transl Sci. 2021;4:980\u20131000. https:\/\/doi.org\/10.1021\/acsptsci.1c00042.","journal-title":"ACS Pharmacol Transl Sci"},{"issue":"12","key":"1573_CR28","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1038\/s41573-022-00472-w","volume":"21","author":"F Vincent","year":"2022","unstructured":"Vincent F, Nueda A, Lee J, Schenone M, Prunotto M, Mercola M. Phenotypic drug discovery: recent successes, lessons learned and new directions. Nat Rev Drug Discov. 2022;21(12):899\u2013914. https:\/\/doi.org\/10.1038\/s41573-022-00472-w.","journal-title":"Nat Rev Drug Discov"},{"key":"1573_CR29","doi-asserted-by":"publisher","first-page":"2327","DOI":"10.1002\/alz.12610","volume":"18","author":"D Lecca","year":"2022","unstructured":"Lecca D, Jung YJ, Scerba MT, Hwang I, Kim YK, Kim S, Modrow S, Tweedie D, Hsueh SC, Liu D, Luo W, Glotfelty E, Li Y, Wang JY, Luo Y, Hoffer BJ, Kim DS, McDevitt RA, Greig NH. Role of chronic neuroinflammation in neuroplasticity and cognitive function: a hypothesis. Alzheimers Dement. 2022;18:2327\u201340. https:\/\/doi.org\/10.1002\/alz.12610.","journal-title":"Alzheimers Dement"},{"issue":"5","key":"1573_CR30","doi-asserted-by":"publisher","first-page":"950","DOI":"10.3390\/pharmaceutics14050950","volume":"14","author":"YR Tsai","year":"2022","unstructured":"Tsai YR, Kim DS, Hsueh SC, Chen KY, Wu JC, Wang JY, Tsou YS, Hwang I, Kim Y, Gil D, Jo EJ, Han BS, Tweedie D, Lecca D, Scerba MT, Selman WR, Hoffer BJ, Greig NH, Chiang YH. 3,6\u2019- and 1,6\u2019-dithiopomalidomide mitigate ischemic stroke in rats and blunt inflammation. Pharmaceutics. 2022;14(5):950. https:\/\/doi.org\/10.3390\/pharmaceutics14050950.","journal-title":"Pharmaceutics"},{"key":"1573_CR31","doi-asserted-by":"publisher","first-page":"8276","DOI":"10.3390\/ijms22158276","volume":"22","author":"PS Huang","year":"2021","unstructured":"Huang PS, Tsai PY, Yang LY, Lecca D, Luo W, Kim DS, Hoffer BJ, Chiang YH, Greig NH, Wang JY. 3,6\u2019-dithiopomalidomide ameliorates hippocampal neurodegeneration, microgliosis and astrogliosis and improves cognitive behaviors in rats with a moderate traumatic brain injury. Int J Mol Sci. 2021;22:8276. https:\/\/doi.org\/10.3390\/ijms22158276.","journal-title":"Int J Mol Sci"},{"issue":"5","key":"1573_CR32","doi-asserted-by":"publisher","first-page":"747","DOI":"10.3390\/biom13050747","volume":"13","author":"KO Kopp","year":"2023","unstructured":"Kopp KO, Greer ME, Glotfelty EJ, Hsueh SC, Tweedie D, Kim DS, Reale M, Vargesson N, Greig NH. A new generation of IMiDs as treatments for neuroinflammatory and neurodegenerative disorders. Biomolecules. 2023;13(5):747. https:\/\/doi.org\/10.3390\/biom13050747.","journal-title":"Biomolecules"},{"issue":"4","key":"1573_CR33","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1016\/j.trci.2017.10.005","volume":"3","author":"RC Mohs","year":"2017","unstructured":"Mohs RC, Greig NH. Drug discovery and development: role of basic biological research. Alzheimers Dement (N Y). 2017;3(4):651\u20137. https:\/\/doi.org\/10.1016\/j.trci.2017.10.005.","journal-title":"Alzheimers Dement (N Y)"},{"issue":"24","key":"1573_CR34","doi-asserted-by":"publisher","first-page":"13442","DOI":"10.3390\/ijms222413442","volume":"22","author":"GC Brown","year":"2021","unstructured":"Brown GC. Neuronal loss after stroke due to microglial phagocytosis of stressed neurons. Int J Mol Sci. 2021;22(24):13442. https:\/\/doi.org\/10.3390\/ijms222413442.","journal-title":"Int J Mol Sci"},{"key":"1573_CR35","doi-asserted-by":"publisher","first-page":"122079","DOI":"10.1016\/j.ijpharm.2022.122079","volume":"625","author":"CM Cardia","year":"2022","unstructured":"Cardia CM, Palmas FM, Casula L, Pisanu A, Marceddu S, Valenti D, Sinico C, Pini E, Scerba MT, Tweedie D, Greig NH, Carta AR, Lai F. Nanocrystals as an effective strategy to improve pomalidomide bioavailability in rodent. Int J Pharm. 2022;625:122079. https:\/\/doi.org\/10.1016\/j.ijpharm.2022.122079.","journal-title":"Int J Pharm"},{"issue":"7428","key":"1573_CR36","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1038\/nature11691.10.1038\/nature11691","volume":"492","author":"J Besnard","year":"2012","unstructured":"Besnard J, Ruda GF, Setola V, Abecassis K, Rodriguiz RM, Huang XP, Norval S, Sassano MF, Shin AI, Webster LA, Simeons FR, Stojanovski L, Prat A, Seidah NG, Constam DB, Bickerton GR, Read KD, Wetsel WC, Gilbert IH, Roth BL, Hopkins AL. Automated design of ligands to polypharmacological profiles. Nature. 2012;492(7428):215\u201320. https:\/\/doi.org\/10.1038\/nature11691.10.1038\/nature11691.","journal-title":"Nature"},{"issue":"2","key":"1573_CR37","doi-asserted-by":"publisher","first-page":"e172626","DOI":"10.1172\/jci.insight.172626","volume":"9","author":"F Asadi","year":"2024","unstructured":"Asadi F, Gunawardana SC, Dolle RE, Piston DW. An orally available compound suppresses glucagon hypersecretion and normalizes hyperglycemia in type 1 diabetes. JCI Insight. 2024;9(2):e172626. https:\/\/doi.org\/10.1172\/jci.insight.172626.","journal-title":"JCI Insight"},{"issue":"2","key":"1573_CR38","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.jneumeth.2009.06.034","volume":"183","author":"D Tweedie","year":"2009","unstructured":"Tweedie D, Luo W, Short RG, Brossi A, Holloway HW, Li Y, Yu QS, Greig NH. A cellular model of inflammation for identifying TNF-alpha synthesis inhibitors. J Neurosci Methods. 2009;183(2):182\u20137. https:\/\/doi.org\/10.1016\/j.jneumeth.2009.06.034.","journal-title":"J Neurosci Methods"},{"key":"1573_CR39","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1186\/1742-2094-9-106","volume":"9","author":"D Tweedie","year":"2012","unstructured":"Tweedie D, Ferguson RA, Fishman K, Frankola KA, Van Praag H, Holloway HW, Luo W, Li Y, Caracciolo L, Russo I, Barlati S, Ray B, Lahiri DK, Bosetti F, Greig NH, Rosi S. Tumor necrosis factor-alpha synthesis inhibitor 3,6\u2019-dithiothalidomide attenuates markers of inflammation, Alzheimer pathology and behavioral deficits in animal models of neuroinflammation and Alzheimer\u2019s disease. J Neuroinflammation. 2012;9:106. https:\/\/doi.org\/10.1186\/1742-2094-9-106.","journal-title":"J Neuroinflammation"},{"key":"1573_CR40","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1186\/1742","volume":"9","author":"SP Gabbita","year":"2012","unstructured":"Gabbita SP, Srivastava MK, Eslami P, Johnson MF, Kobritz NK, Tweedie D, Greig NH, Zemlan FP, Sharma SP, Harris-White ME. Early intervention with a small molecule inhibitor for tumor necrosis factor-\u03b1 prevents cognitive deficits in a triple transgenic mouse model of Alzheimer\u2019s disease. J Neuroinflammation. 2012;9:99. https:\/\/doi.org\/10.1186\/1742.","journal-title":"J Neuroinflammation"},{"issue":"4","key":"1573_CR41","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1161\/01.STR.17.4.73","volume":"17","author":"ST Chen","year":"1986","unstructured":"Chen ST, Hsu CY, Hogan EL, Maricq H, Balentine JD. A model of focal ischemic stroke in the rat: reproducible extensive cortical infarction. Stroke. 1986;17(4):738\u201343. https:\/\/doi.org\/10.1161\/01.STR.17.4.73.","journal-title":"Stroke"},{"issue":"2","key":"1573_CR42","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1002\/jnr.21865","volume":"87","author":"H Shen","year":"2009","unstructured":"Shen H, Luo Y, Kuo CC, Deng X, Chang CF, Harvey BK, Hoffer BJ, Wang Y. 9-Cis-retinoic acid reduces ischemic brain injury in rodents via bone morphogenetic protein. J Neurosci Res. 2009;87(2):545\u201355. https:\/\/doi.org\/10.1002\/jnr.21865.","journal-title":"J Neurosci Res"},{"key":"1573_CR43","doi-asserted-by":"publisher","unstructured":"Li Y, Perry TA, Kindy MS, Harvery BK, Tweedie D, Holloway HW, Powers K, ShenH, Egan JM, Sambamurti K, Bross A, Lahiri DK, Mattson MP, Hoffer BJ, Wang Y, Greig NH. GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism. Proc Natl Acad Sci U S A 2009; 106(4): 1285\u20131290. https:\/\/doi.org\/10.1073\/pnas.0806720106","DOI":"10.1073\/pnas.0806720106"},{"issue":"16","key":"1573_CR44","doi-asserted-by":"publisher","first-page":"3615","DOI":"10.1097\/00001756-199811160-00012","volume":"9","author":"CV Borlongan","year":"1998","unstructured":"Borlongan CV, Hida H, Nishino H. Early assessment of motor dysfunctions aids in successful occlusion of the middle cerebral artery. NeuroReport. 1998;9(16):3615\u201321. https:\/\/doi.org\/10.1097\/00001756-199811160-00012.","journal-title":"NeuroReport"},{"issue":"7 Pt 2","key":"1573_CR45","doi-asserted-by":"publisher","first-page":"5372","DOI":"10.1523\/JNEUROSCI.15-07-05372.1995","volume":"15","author":"CV Borlongan","year":"1995","unstructured":"Borlongan CV, Sanberg PR. Elevated body swing test: a new behavioral parameter for rats with 6-hydroxydopamine-induced hemiparkinsonism. J Neurosci. 1995;15(7 Pt 2):5372\u20138. https:\/\/doi.org\/10.1523\/JNEUROSCI.15-07-05372.1995.","journal-title":"J Neurosci"},{"key":"1573_CR46","doi-asserted-by":"publisher","first-page":"303","DOI":"10.4103\/0976-500X.119726","volume":"4","author":"J Charan","year":"2013","unstructured":"Charan J, Kantharia ND. How to calculate sample size in animal studies? J Pharmacol Pharmacother. 2013;4:303\u20136. https:\/\/doi.org\/10.4103\/0976-500X.119726.","journal-title":"J Pharmacol Pharmacother"},{"issue":"3","key":"1573_CR47","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1084\/jem.173.3.699","volume":"173","author":"EP Sampaio","year":"1991","unstructured":"Sampaio EP, Sarno EN, Galilly R, Cohn ZA, Kaplan G. Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes. J Exp Med. 1991;173(3):699\u2013703. https:\/\/doi.org\/10.1084\/jem.173.3.699.","journal-title":"J Exp Med"},{"key":"1573_CR48","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1016\/S0090-9556(24)14938-0","volume":"27","author":"RS Obach","year":"1999","unstructured":"Obach RS. Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: an examination of in vitro half-life approach and nonspecific binding to microsomes. Drug Metab Dispos. 1999;27:1350\u20139.","journal-title":"Drug Metab Dispos"},{"key":"1573_CR49","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1080\/17474086.2024.2382897","volume":"17","author":"Y Liu","year":"2024","unstructured":"Liu Y, Mo CC, Hartley-Brown MA, Sperling AS, Midha S, Yee AJ, Bianchi G, Piper C, Tattersall A, Nadeem O, Laubach JP, Richardson PG. Targeting Ikaros and Aiolos: reviewing novel protein degraders for the treatment of multiple myeloma, with a focus on iberdomide and mezigdomide. Expert Rev Hematol. 2024;17:445\u201365. https:\/\/doi.org\/10.1080\/17474086.2024.2382897.","journal-title":"Expert Rev Hematol"},{"key":"1573_CR50","doi-asserted-by":"publisher","first-page":"104010","DOI":"10.1016\/j.drudis.2024.104010","volume":"29","author":"MJ Nutt","year":"2024","unstructured":"Nutt MJ, Stewart SG. Strengthening molecular glues: design strategies for improving thalidomide analogs as cereblon effectors and anticancer agents. Drug Discov Today. 2024;29:104010. https:\/\/doi.org\/10.1016\/j.drudis.2024.104010.","journal-title":"Drug Discov Today"},{"issue":"9","key":"1573_CR51","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1038\/nsmb.2874","volume":"21","author":"PP Chamberlain","year":"2014","unstructured":"Chamberlain PP, Lopez-Girona A, Miller K, Carmel G, Pagarigan B, Chie-Leon B, Rychak E, Corral LG, Ren YJ, Wang M, Riley M, Delker SL, Ito T, Ando H, Mori T, Hirano Y, Handa H, Hakoshima T, Daniel TO, Cathers BE. Structure of the human Cereblon-DDB1-lenalidomide complex reveals basis for responsiveness to thalidomide analogs. Nat Struct Mol Biol. 2014;21(9):803\u20139. https:\/\/doi.org\/10.1038\/nsmb.2874.","journal-title":"Nat Struct Mol Biol"},{"issue":"2","key":"1573_CR52","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/j.hoc.2024.01.001","volume":"38","author":"H Lee","year":"2024","unstructured":"Lee H, Neri P, Bahlis NJ. Cereblon-targeting ligase degraders in myeloma: mechanisms of action and resistance. Hematol Oncol Clin North Am. 2024;38(2):305\u201319. https:\/\/doi.org\/10.1016\/j.hoc.2024.01.001.","journal-title":"Hematol Oncol Clin North Am"},{"key":"1573_CR53","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1126\/science.1177319","volume":"327","author":"T Ito","year":"2010","unstructured":"Ito T, Ando H, Suzuki T, Ogura T, Hotta K, Imamura Y, Yamaguchi Y, Handa H. Identification of a primary target of thalidomide teratogenicity. Science. 2010;327:1345\u201350. https:\/\/doi.org\/10.1126\/science.1177319.","journal-title":"Science"},{"key":"1573_CR54","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/nature13527","volume":"512","author":"ES Fischer","year":"2014","unstructured":"Fischer ES, B\u00f6hm K, Lydeard JR, Yang H, Stadler MB, Cavadini S, Nagel J, Serluca F, Acker V, Lingaraju GM, Tichkule RB, Schebesta M, Forrester WC, Schirle M, Hassiepen U, Ottl J, Hild M, Beckwith RE, Harper JW, Jenkins JL, Thom\u00e4 NH. Structure of the DDB1-CRBN E3 ubiquitin ligase in complex with thalidomide. Nature. 2014;512:49\u201353. https:\/\/doi.org\/10.1038\/nature13527.","journal-title":"Nature"},{"key":"1573_CR55","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1038\/nsmb.2874","volume":"21","author":"PP Chamberlain","year":"2014","unstructured":"Chamberlain PP, Lopez-Girona A, Miller K, Carmel G, Pagarigan B, Chie-Leon B, Rychak E, Corral LG, Ren YJ, Wang M, Riley M, Delker SL, Ito T, Ando H, Mori T, Hirano Y, Handa H, Hakoshima T, Daniel TO, Cathers BE. Structure of the human Cereblon-DDB1-lenalidomide complex reveals basis for responsiveness to thalidomide analogs. Nat Struct Mol Biol. 2014;21:803\u20139. https:\/\/doi.org\/10.1038\/nsmb.2874.","journal-title":"Nat Struct Mol Biol"},{"key":"1573_CR56","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1038\/s41598-018-19202-7","volume":"8","author":"T Mori","year":"2018","unstructured":"Mori T, Ito T, Liu S, Ando H, Sakamoto S, Yamaguchi Y, Tokunaga E, Shibata N, Handa H, Hakoshima T. Structural basis of thalidomide enantiomer binding to cereblon. Sci Rep. 2018;8:1294. https:\/\/doi.org\/10.1038\/s41598-018-19202-7.","journal-title":"Sci Rep"},{"key":"1573_CR57","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1182\/blood-2012-02-412783","volume":"120","author":"M Chesi","year":"2012","unstructured":"Chesi M, Matthews GM, Garbitt VM, Palmer SE, Shortt J, Lefebure M, Stewart AK, Johnstone RW, Bergsagel PL. Drug response in a genetically engineered mouse model of multiple myeloma is predictive of clinical efficacy. Blood. 2012;120:376\u201385. https:\/\/doi.org\/10.1182\/blood-2012-02-412783.","journal-title":"Blood"},{"key":"1573_CR58","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1038\/nature14610","volume":"523","author":"J Kr\u00f6nke","year":"2015","unstructured":"Kr\u00f6nke J, Fink EC, Hollenbach PW, MacBeth KJ, Hurst SN, Udeshi ND, Chamberlain PP, Mani DR, Man HW, Gandhi AK, Svinkina T, Schneider RK, McConkey M, J\u00e4r\u00e5s M, Griffiths E, Wetzler M, Bullinger L, Cathers BE, Carr SA, Chopra R, Ebert BL. Lenalidomide induces ubiquitination and degradation of CK1\u03b1 in del(5q) MDS. Nature. 2015;523:183\u20138. https:\/\/doi.org\/10.1038\/nature14610.","journal-title":"Nature"},{"issue":"46","key":"1573_CR59","doi-asserted-by":"publisher","first-page":"11802","DOI":"10.1073\/pnas","volume":"115","author":"Y Gemechu","year":"2018","unstructured":"Gemechu Y, Millrine D, Hashimoto S, Prakash J, Sanchenkova K, Metwally H, Gyanu P, Kang S, Kishimoto T. Humanized cereblon mice revealed two distinct therapeutic pathways of immunomodulatory drugs. Proc Natl Acad Sci U S A. 2018;115(46):11802\u20137. https:\/\/doi.org\/10.1073\/pnas.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"1573_CR60","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1093\/intimm\/dxw005","volume":"28","author":"D Millrine","year":"2016","unstructured":"Millrine D, Miyata H, Tei M, Dubey P, Nyati K, Nakahama T, Gemechu Y, Ripley B, Kishimoto T. Immunomodulatory drugs inhibit TLR4-induced type-1 interferon production independently of Cereblon via suppression of the TRIF\/IRF3 pathway. Int Immunol. 2016;28(6):307\u201315. https:\/\/doi.org\/10.1093\/intimm\/dxw005.","journal-title":"Int Immunol"},{"key":"1573_CR61","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1016\/j.molmed.2017.02.006","volume":"23","author":"D Millrine","year":"2017","unstructured":"Millrine D, Kishimoto T. A brighter side to thalidomide: its potential use in immunological disorders. Trends Mol Med. 2017;23:348\u201361. https:\/\/doi.org\/10.1016\/j.molmed.2017.02.006.","journal-title":"Trends Mol Med"},{"key":"1573_CR62","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s12929-023-00907-5","volume":"30","author":"D Lecca","year":"2023","unstructured":"Lecca D, Hsueh SC, Luo W, Tweedie D, Kim DS, Baig AM, Vargesson N, Kim YK, Hwang I, Kim S, Hoffer BJ, Chiang YH, Greig NH. Novel, thalidomide-like, non-cereblon binding drug tetrafluorobornylphthalimide mitigates inflammation and brain injury. J Biomed Sci. 2023;30:16. https:\/\/doi.org\/10.1186\/s12929-023-00907-5.","journal-title":"J Biomed Sci"},{"key":"1573_CR63","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1084\/jem.177.6.1675","volume":"177","author":"AL Moreira","year":"1993","unstructured":"Moreira AL, Sampaio EP, Zmuidzinas A, Frindt P, Smith KA, Kaplan G. Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation. J Exp Med. 1993;177:1675\u201380. https:\/\/doi.org\/10.1084\/jem.177.6.1675.","journal-title":"J Exp Med"},{"key":"1573_CR64","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1038\/nrc1323","volume":"4","author":"JB Bartlett","year":"2004","unstructured":"Bartlett JB, Dredge K, Dalgleish AG. The evolution of thalidomide and its IMiD derivatives as anticancer agents. Nat Rev Cancer. 2004;4:314.","journal-title":"Nat Rev Cancer"},{"key":"1573_CR65","doi-asserted-by":"publisher","first-page":"3017","DOI":"10.1210\/jc.2004-1946","volume":"90","author":"T Yagyu","year":"2005","unstructured":"Yagyu T, Kobayashi H, Matsuzaki H, Wakahara K, Kondo T, Kurita N, Sekino H, Inagaki K, Suzuki M, Kanayama N, Terao T. Thalidomide inhibits tumor necrosis factor-alpha-induced interleukin-8 expression in endometriotic stromal cells, possibly through suppression of nuclear factor-kappaB activation. J Clin Endocrinol Metab. 2005;90:3017\u201321. https:\/\/doi.org\/10.1210\/jc.2004-1946.","journal-title":"J Clin Endocrinol Metab"},{"key":"1573_CR66","doi-asserted-by":"publisher","first-page":"22382","DOI":"10.1074\/jbc.M100938200","volume":"276","author":"JA Keifer","year":"2001","unstructured":"Keifer JA, Guttridge DC, Ashburner BP, Baldwin AS. Jr Inhibition of NF-kappa B activity by thalidomide through suppression of IkappaB kinase activity. J Biol Chem. 2001;276:22382\u20137. https:\/\/doi.org\/10.1074\/jbc.M100938200.","journal-title":"J Biol Chem"},{"key":"1573_CR67","doi-asserted-by":"publisher","first-page":"380","DOI":"10.3892\/etm.2022.11307","volume":"23","author":"AA Palmer","year":"2022","unstructured":"Palmer AA, Stezoski JP, Janesko-Feldman K, Kochanek PM, Drabek T. Targeting TNF\u03b1-mediated cytotoxicity using thalidomide after experimental cardiac arrest in rats: an exploratory study. Exp Ther Med. 2022;23:380. https:\/\/doi.org\/10.3892\/etm.2022.11307.","journal-title":"Exp Ther Med"},{"key":"1573_CR68","doi-asserted-by":"publisher","first-page":"585146","DOI":"10.3389\/fimmu.2020.585146","volume":"11","author":"A Zamyatina","year":"2020","unstructured":"Zamyatina A, Heine H. Lipopolysaccharide recognition in the crossroads of TLR4 and caspase-4\/11 mediated inflammatory pathways. Front Immunol. 2020;11:585146. https:\/\/doi.org\/10.3389\/fimmu.2020.585146.","journal-title":"Front Immunol"},{"key":"1573_CR69","doi-asserted-by":"publisher","first-page":"704202","DOI":"10.1155\/2010\/704202","volume":"2010","author":"F Arslan","year":"2010","unstructured":"Arslan F, Keogh B, McGuirk P, Parker AE. TLR2 and TLR4 in ischemia reperfusion injury. Mediators Inflamm. 2010;2010:704202. https:\/\/doi.org\/10.1155\/2010\/704202.","journal-title":"Mediators Inflamm"},{"issue":"7","key":"1573_CR70","doi-asserted-by":"publisher","first-page":"e2313","DOI":"10.1038\/cddis.2016.226","volume":"7","author":"Y Min","year":"2016","unstructured":"Min Y, Wi SM, Kang JA, Yang T, Park CS, Park SG, Chung S, Shim JH, Chun E, Lee KY. Cereblon negatively regulates TLR4 signaling through the attenuation of ubiquitination of TRAF6. Cell Death Disease. 2016;7(7):e2313. https:\/\/doi.org\/10.1038\/cddis.2016.226.","journal-title":"Cell Death Disease"},{"issue":"4","key":"1573_CR71","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1093\/hmg\/ddx433","volume":"27","author":"L Zhou","year":"2018","unstructured":"Zhou L, Hao Z, Wang G, Xu G. Cereblon suppresses the formation of pathogenic protein aggregates in a p62-dependent manner. Human Molecul Genet. 2018;27(4):667\u201378. https:\/\/doi.org\/10.1093\/hmg\/ddx433.","journal-title":"Human Molecul Genet"},{"key":"1573_CR72","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/s1074-7613(00)80038-2","volume":"10","author":"D Kontoyiannis","year":"1999","unstructured":"Kontoyiannis D, Pasparakis M, Pizarro TT, Cominelli F, Kollias G. Impaired on\/off regulation of TNF biosynthesis in mice lacking TNF AU-rich elements: implications for joint and gut-associated immunopathologies. Immunity. 1999;10:387\u201398. https:\/\/doi.org\/10.1016\/s1074-7613(00)80038-2.","journal-title":"Immunity"},{"key":"1573_CR73","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.cyto.2008.11.010","volume":"45","author":"AJ Asirvatham","year":"2009","unstructured":"Asirvatham AJ, Magner WJ, Tomasi TB. miRNA regulation of cytokine genes. Cytokine. 2009;45:58\u201369. https:\/\/doi.org\/10.1016\/j.cyto.2008.11.010.","journal-title":"Cytokine"},{"key":"1573_CR74","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1111\/j.1365-2141.2004.05286.x","volume":"128","author":"T Hayashi","year":"2005","unstructured":"Hayashi T, Hideshima T, Akiyama M, Podar K, Yasui H, Raje N, Kumar S, Chauhan D, Treon SP, Richardson P, Anderson KC. Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application. Br J Haematol. 2005;128:192\u2013203. https:\/\/doi.org\/10.1111\/j.1365-2141.2004.05286.x.","journal-title":"Br J Haematol"},{"key":"1573_CR75","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1111\/j.1365-2141.2004.05286.x","volume":"8","author":"A Tuttolomondo","year":"2014","unstructured":"Tuttolomondo A, Pecoraro R, Pinto A. Studies of selective TNF inhibitors in the treatment of brain injury from stroke and trauma: a review of the evidence to date. Drug Des Devel Ther. 2014;8:2221\u201338. https:\/\/doi.org\/10.1111\/j.1365-2141.2004.05286.x.","journal-title":"Drug Des Devel Ther"},{"issue":"2","key":"1573_CR76","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1038\/nm.1927","volume":"15","author":"A Liesz","year":"2009","unstructured":"Liesz A, Suri-Payer E, Veltkamp C, Doerr H, Sommer C, Rivest S, Giese T, Veltkamp R. Regulatory T cells are key cerebroprotective immunomodulators in acute experimental stroke. Nat Med. 2009;15(2):192\u20139. https:\/\/doi.org\/10.1038\/nm.1927.","journal-title":"Nat Med"},{"key":"1573_CR77","doi-asserted-by":"publisher","first-page":"828447","DOI":"10.3389\/fimmu.2022.828447","volume":"13","author":"H Zhu","year":"2022","unstructured":"Zhu H, Hu S, Li Y, Sun Y, Xiong X, Hu X, Chen J, Qiu S. Interleukins and ischemic stroke Front Immunol. 2022;13:828447. https:\/\/doi.org\/10.3389\/fimmu.2022.828447.","journal-title":"Interleukins and ischemic stroke Front Immunol"},{"key":"1573_CR78","doi-asserted-by":"publisher","first-page":"6423244","DOI":"10.1155\/2021\/6423244","volume":"2021","author":"W Sun","year":"2021","unstructured":"Sun W, Wang S, Nan S. The prognostic determinant of interleukin-10 in patients with acute ischemic stroke: an analysis from the perspective of disease management. Dis Markers. 2021;2021:6423244. https:\/\/doi.org\/10.1155\/2021\/6423244.","journal-title":"Dis Markers"},{"key":"1573_CR79","doi-asserted-by":"publisher","first-page":"1967","DOI":"10.3390\/ijms17121967","volume":"17","author":"A Bonaventura","year":"2016","unstructured":"Bonaventura A, Liberale L, Vecchi\u00e9 A, Casula M, Carbone F, Dallegri F, Montecucco F. Update on inflammatory biomarkers and treatments in ischemic stroke. Int J Mol Sci. 2016;17:1967. https:\/\/doi.org\/10.3390\/ijms17121967.","journal-title":"Int J Mol Sci"},{"key":"1573_CR80","unstructured":"European Medicines Agency. Assessment Report: Pomalidomide Celgene [Internet]. 2013. [Accessed 02\/10\/2025]. https:\/\/www.ema.europa.eu\/documents\/assessment-report\/pomalidomide-celgene-epar-public-assessment-report_en.pdf"},{"issue":"3","key":"1573_CR81","doi-asserted-by":"publisher","first-page":"e0193800","DOI":"10.1371\/journal.pone.0193800","volume":"13","author":"YH Nam","year":"2018","unstructured":"Nam YH, Brensinger CM, Bilker WB, Leonard CE, Kasner SE, Grosser T, Li X, Hennessy S. Nonsteroidal anti-inflammatory drug choice and adverse outcomes in clopidogrel users: a retrospective cohort study. PLoS ONE. 2018;13(3):e0193800. https:\/\/doi.org\/10.1371\/journal.pone.0193800.","journal-title":"PLoS ONE"},{"key":"1573_CR82","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/j.jpba.2013.08.036","volume":"88","author":"Y Jiang","year":"2014","unstructured":"Jiang Y, Wang J, Rozewski DM, Kolli S, Wu CH, Chen CS, Yang X, Hofmeister CC, Byrd JC, Johnson AJ, Phelps MA. Sensitive liquid chromatography\/mass spectrometry methods for quantification of pomalidomide in mouse plasma and brain tissue. J Pharm Biomed Anal. 2014;88:262\u20138. https:\/\/doi.org\/10.1016\/j.jpba.2013.08.036.","journal-title":"J Pharm Biomed Anal"},{"key":"1573_CR83","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.artres.2018.05.004","volume":"22","author":"K Keller","year":"2018","unstructured":"Keller K, Geyer M, Munzel T, Ostad MA. Gender-differences in prevalence and outcome of ischemic stroke and promoting factors of atrial thrombi. Artery Res. 2018;22:68\u201378. https:\/\/doi.org\/10.1016\/j.artres.2018.05.004.","journal-title":"Artery Res"},{"key":"1573_CR84","doi-asserted-by":"publisher","first-page":"3120","DOI":"10.1210\/en.2018-00465","volume":"159","author":"M Roy-O'Reilly","year":"2018","unstructured":"Roy-O\u2019Reilly M, McCullough LD. Age and sex are critical factors in ischemic stroke pathology. Endocrinology. 2018;159:3120\u201331. https:\/\/doi.org\/10.1210\/en.2018-00465.","journal-title":"Endocrinology"},{"key":"1573_CR85","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1007\/s00281-022-00969-x","volume":"45","author":"MB Tariq","year":"2023","unstructured":"Tariq MB, Lee J, McCullough LD. Sex differences in the inflammatory response to stroke. Semin Immunopathol. 2023;45:295\u2013313. https:\/\/doi.org\/10.1007\/s00281-022-00969-x.","journal-title":"Semin Immunopathol"},{"key":"1573_CR86","doi-asserted-by":"publisher","first-page":"1164258","DOI":"10.3389\/fimmu.2023.1164258","volume":"14","author":"X Zhong","year":"2023","unstructured":"Zhong X, Sun Y, Lu Y, Xu L. Immunomodulatory role of estrogen in ischemic stroke: neuroinflammation and effect of sex. Front Immunol. 2023;14:1164258. https:\/\/doi.org\/10.3389\/fimmu.2023.1164258.","journal-title":"Front Immunol"},{"key":"1573_CR87","doi-asserted-by":"publisher","first-page":"194","DOI":"10.3389\/fnagi.2017.00194","volume":"9","author":"B Spittau","year":"2017","unstructured":"Spittau B. Aging microglia\u2014phenotypes, functions and implications for age-related neurodegenerative diseases. Front Aging Neurosci. 2017;9:194. https:\/\/doi.org\/10.3389\/fnagi.2017.00194.","journal-title":"Front Aging Neurosci"},{"key":"1573_CR88","doi-asserted-by":"publisher","first-page":"1960","DOI":"10.3389\/fimmu.2017.01960","volume":"8","author":"T Fulop","year":"2018","unstructured":"Fulop T, Larbi A, Dupuis G, Le Page A, Frost EH, Cohen AA, Witkowski JM, Franceschi C. Immunosenescence and inflammaging as two sides of the same coin: friends or foes? Front Immunol. 2018;8:1960. https:\/\/doi.org\/10.3389\/fimmu.2017.01960.","journal-title":"Front Immunol"},{"key":"1573_CR89","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.3390\/ijms24031869","volume":"24","author":"FL Andronie-Cioara","year":"2023","unstructured":"Andronie-Cioara FL, Ardelean AI, Nistor-Cseppento CD, Jurcau A, Jurcau MC, Pascalau N, Marcu F. Molecular mechanisms of neuroinflammation in aging and Alzheimer\u2019s disease progressioN. Int J Mol Sci. 2023;24:1869. https:\/\/doi.org\/10.3390\/ijms24031869.","journal-title":"Int J Mol Sci"}],"container-title":["GeroScience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11357-025-01573-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11357-025-01573-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11357-025-01573-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T07:48:59Z","timestamp":1757144939000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11357-025-01573-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,17]]},"references-count":89,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,8]]}},"alternative-id":["1573"],"URL":"https:\/\/doi.org\/10.1007\/s11357-025-01573-1","relation":{},"ISSN":["2509-2723"],"issn-type":[{"value":"2509-2723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,17]]},"assertion":[{"value":"16 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This is a preclinical (non-clinical) research study that does not require ethics approval and consent to participate of human subjects. All preclinical animal studies were undertaken on fully approved Institutional Animal Care and Use Committee protocols (see Materials and Methods, Section C).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors have read, approved, and have provided their consent for submission and publication of the present manuscript in GeroScience.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"DSK and EH are employed by and have stock in Aevis Bio Inc., which has patent coverage on 3-MP. All other authors declare a lack of conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}